Literature DB >> 2986504

Thrombocytopenic purpura in narcotics addicts.

S Savona, M A Nardi, E T Lennette, S Karpatkin.   

Abstract

Since November 1982 we have seen an association of thrombocytopenic purpura with chronic narcotic addiction in 70 patients with a mean platelet count of 53000 +/- 4000 (SE); 33 had stopped taking intravenous drugs for an average of 21.2 +/- 4.7 months; 13 of 15 had elevated antibody titers for a virus related to the acquired immunodeficiency syndrome. Platelet-bound IgG, IgM, and complement levels were 16.7-, 5.6-, and 3.1-fold greater than control values, respectively, and 2.6-, 1.9-, and 2.4-fold greater than values in 25 patients with classic autoimmune thrombocytopenic purpura studied at the same time. Thirty-three of thirty-six addicts had elevated circulating immune complexes, whereas 8 patients with autoimmune thrombocytopenia had no elevation. Eleven of eighteen addicts had positive serum platelet-reactive IgG titers, compared to 5 of 19 patients with classic autoimmune thrombocytopenia. The platelet-reactive IgG in sera of addicts was composed of 7S IgG antibody as well as high molecular weight (immune complex) IgG. Thus, chronic addicts appear to have a new immunologic platelet disorder associated with the presence of 7S IgG antiplatelet antibody, like patients with classic autoimmune thrombocytopenic purpura, and immune complex associated nonspecific platelet IgG, like male homosexual patients with thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2986504     DOI: 10.7326/0003-4819-102-6-737

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  22 in total

1.  Expression of CD4 by human megakaryocytes.

Authors:  R S Basch; Y H Kouri; S Karpatkin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Complement-independent Ab-induced peroxide lysis of platelets requires 12-lipoxygenase and a platelet NADPH oxidase pathway.

Authors:  Michael Nardi; Steven J Feinmark; Liang Hu; Zongdong Li; Simon Karpatkin
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

3.  GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia.

Authors:  M A Nardi; L X Liu; S Karpatkin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

Review 4.  Medical complications of intravenous drug use.

Authors:  M D Stein
Journal:  J Gen Intern Med       Date:  1990 May-Jun       Impact factor: 5.128

5.  Anti-F(ab')2 antibodies in thrombocytopenic patients at risk for acquired immunodeficiency syndrome.

Authors:  J R Yu; E T Lennette; S Karpatkin
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

6.  The epidemiology of immune thrombocytopenia.

Authors:  W F Schlech; C Nesdoly; N Meagher; J Turner; D Dickey
Journal:  Can J Infect Dis       Date:  1992-11

Review 7.  HIV-1-associated thrombocytopenia. The role of splenectomy.

Authors:  D S Tyler; S Shaunak; J A Bartlett; J D Iglehart
Journal:  Ann Surg       Date:  1990-02       Impact factor: 12.969

8.  Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia.

Authors:  Zongdong Li; Michael A Nardi; Simon Karpatkin
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

9.  Sequestration of anti-platelet GPIIIa antibody in rheumatoid factor immune complexes of human immunodeficiency virus 1 thrombocytopenic patients.

Authors:  S Karpatkin; M A Nardi; K B Hymes
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

10.  Autoimmune anti-HIV-1gp120 antibody with antiidiotype-like activity in sera and immune complexes of HIV-1-related immunologic thrombocytopenia.

Authors:  S Karpatkin; M Nardi
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.